MARKET

PCRX

PCRX

Pacira BioSciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

69.62
-1.75
-2.45%
Opening 13:28 03/03 EST
OPEN
71.38
PREV CLOSE
71.36
HIGH
71.56
LOW
69.18
VOLUME
176.08K
TURNOVER
--
52 WEEK HIGH
80.00
52 WEEK LOW
27.46
MARKET CAP
3.02B
P/E (TTM)
21.21
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Pacira BioSciences to Present at the 2021 Barclays Global Healthcare Conference
Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 2021 Barclays Global Healthcare Conference at 10:55 AM ET on Tuesday, March 9, 2021. Live audio of the virtual event can be accessed by visiting the "Events" page of the co...
GlobeNewswire · 5h ago
DJ Pacira BioSciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 2d ago
DJ Pacira BioSciences Price Target Raised to $86.00/Share From $70.00 by HC Wainwright & Co.
Dow Jones · 2d ago
10-K: PACIRA BIOSCIENCES, INC.
(EDGAR Online via COMTEX) -- Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Management's Discussion and...
Edgar Online - (EDG = 10Q, 10K) · 2d ago
--Analyst Actions: HC Wainwright & Co. Adjusts Price Target on Pacira BioSciences to $86 From $70, Maintains Buy Rating
MT Newswires · 2d ago
Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates
Most Food and Drug Administration decisions scheduled for February were positive, and more importantly five new molecular entities passed FDA muster.
Benzinga · 3d ago
Pacira's (PCRX) Q4 Earnings Top Estimates, Revenues Miss
Zacks.com · 5d ago
Pacira Pharmaceuticals (PCRX) Gets a Hold Rating from Northland Securities
Northland Securities analyst Tim Chiang maintained a Hold rating on Pacira Pharmaceuticals (PCRX) today and set a price target of $75.00. The company's
SmarterAnalyst · 5d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PCRX. Analyze the recent business situations of Pacira BioSciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PCRX stock price target is 79.38 with a high estimate of 94.00 and a low estimate of 54.00.
EPS
Institutional Holdings
Institutions: 402
Institutional Holdings: 53.13M
% Owned: 122.30%
Shares Outstanding: 43.44M
TypeInstitutionsShares
Increased
104
3.36M
New
50
57.55K
Decreased
84
1.39M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.90%
Pharmaceuticals & Medical Research
-1.26%
Key Executives
Chairman/Chief Executive Officer/Director
David Stack
President
Max Reinhardt
Chief Financial Officer
Charles Reinhart
Chief Administrative Officer/Secretary
Kristen Williams
Other
Charles Laranjeira
Other
Dennis McLoughlin
Other
Roy Winston
Lead Director/Independent Director
Paul Hastings
Director
Christopher Christie
Independent Director
Laura Brege
Independent Director
Mark Froimson
Independent Director
Yvonne Greenstreet
Independent Director
Mark Kronenfeld
Independent Director
John Longenecker
Independent Director
Gary Pace
Independent Director
Andreas Wicki
  • Dividends
  • Splits
  • Insider Activity
No Data
About PCRX
Pacira BioSciences, Inc., formerly Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).

Webull offers kinds of Pacira Biosciences Inc stock information, including NASDAQ:PCRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PCRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PCRX stock methods without spending real money on the virtual paper trading platform.